Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 13/20 | 0.59 |
| ▸ | CTSL | P07711 | 12/20 | 0.59 |
| ▸ | CTSB | P07858 | 7/20 | 0.59 |
| ▸ | CTSK | P43235 | 6/20 | 0.56 |
| ▸ | TACR1 | P25103 | 1/20 | 0.54 |
| ▸ | ELANE | P08246 | 1/20 | 0.53 |
| ▸ | SYK | P43405 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4119423 | 1.00 | CTSS (0.59) | CTSSCTSLCTSBCTSKTACR1 | |
| SCHEMBL16847818 | 0.86 | CTSS (0.53) | CTSSCTSLCTSBCTSKTACR1 | |
| SCHEMBL6182846 | 0.84 | CTSS (0.52) | CTSSCTSLCTSBCTSKTACR1 | |
| SCHEMBL6311227 | 0.82 | CTSL (0.60) | CTSSCTSLCTSBCTSKTACR1 | |
| SCHEMBL6311222 | 0.82 | CTSL (0.60) | CTSSCTSLCTSBCTSKTACR1 | |
| SCHEMBL6320730 | 0.82 | CTSL (0.60) | CTSSCTSLCTSBCTSKTACR1 | |
| SCHEMBL6311732 | 0.81 | CTSS (0.62) | CTSSCTSLCTSBCTSKTACR1 | |
| SCHEMBL6312473 | 0.81 | CTSS (0.62) | CTSSCTSLCTSBCTSKTACR1 | |
| SCHEMBL6311738 | 0.81 | CTSS (0.62) | CTSSCTSLCTSBCTSKTACR1 | |
| SCHEMBL498416 | 0.81 | SYK (0.58) | CTSSCTSLCTSBCTSKTACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720058-A2 | BIFUNCTIONAL DEGRADERS AND USES THEREOF | Casma Therapeutics, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| WO-2024249291-A2 | BIFUNCTIONAL DEGRADERS AND USES THEREOF | CASMA THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| US-20110086893-A1 | OXA- AND THIADIAZOLES AND THEIR USE AS METALLOPROTEINASE INHIBITORS | VERNALIS (OXFORD) LTD (GB) | 2011-04-14 | — | — | US | disclosed |
| US-20110028447-A1 | INDAZOLE DERIVATIVES | PFIZER INC. | 2011-02-03 | — | — | US | disclosed |
| US-20110028447-A1 | INDAZOLE DERIVATIVES | PFIZER INC. | 2011-02-03 | — | — | US | disclosed |
| US-20100035943-A1 | Oxa-and thiadiazoles and their use as metalloproteinase inhibitors | VERNALIS (OXFORD) LTD (GB) | 2010-02-11 | — | — | US | disclosed |
| EP-2114897-A2 | BENZIMIDAZOLONE DERIVATIVES | Pfizer Products Inc. (US) | 2009-11-11 | — | — | EP | disclosed |
| WO-2009106980-A2 | INDAZOLE DERIVATIVES | PFIZER INC. (US) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009106982-A1 | INDAZOLE DERIVATIVES | PFIZER INC. (US) | 2009-09-03 | — | — | WO | disclosed |
| US-20080227833-A1 | OXA- AND THIADIAZOLES AND THEIR USE AS METALLOPROTEINASE INHIBITORS | VERNALIS (OXFORD) LTD (GB) | 2008-09-18 | — | — | US | disclosed |
| US-7358265-B2 | Oxa-and thiadiazoles and their use as metalloproteinase inhibitors | VERNALIS (R&D) LTD | 2008-04-15 | — | — | US | disclosed |
| WO-2008032164-A2 | BENZIMIDAZOLONE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| EP-1476438-B1 | OXA- AND THIADIAZOLES AND THEIR USE AS METALLOPROTEINASE INHIBITORS | VERNALIS R&D LTD (GB) | 2007-04-18 | — | — | EP | disclosed |
| US-20050222189-A1 | Oxa-and thiadiazoles and their use as metalloproteinase inhibitors | VERNALIS (OXFORD) LTD (GB) | 2005-10-06 | — | — | US | disclosed |
| WO-2004101537-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LTD (GB) | 2004-11-25 | — | — | WO | disclosed |
| EP-1476438-A1 | OXA- AND THIADIAZOLES AND THEIR USE AS METALLOPROTEINASE INHIBITORS | Vernalis (Oxford) Ltd (GB) | 2004-11-17 | — | — | EP | disclosed |
| WO-2003070711-A1 | OXA- AND THIADIAZOLES AND THEIR USE AS METALLOPROTEINASE INHIBITORS | VERNALIS (OXFORD) LTD (GB) | 2003-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222189-A1 | Oxa-and thiadiazoles and their use as metalloproteinase inhibitors | MMP9, TIMP3, MMP13 | CTSS 446/4885CTSL 432/4885CTSB 272/4885 |
| US-20100035943-A1 | Oxa-and thiadiazoles and their use as metalloproteinase inhibitors | MMP12, TIMP3, MMP9 | CTSS 744/4885CTSL 544/4885CTSB 534/4885 |
| US-20080227833-A1 | OXA- AND THIADIAZOLES AND THEIR USE AS METALLOPROTEINASE INHIBITORS | MMP12, TIMP3, MMP9 | CTSS 744/4885CTSL 544/4885CTSB 534/4885 |
| US-20110086893-A1 | OXA- AND THIADIAZOLES AND THEIR USE AS METALLOPROTEINASE INHIBITORS | MMP12, TIMP3, MMP9 | CTSS 744/4885CTSL 544/4885CTSB 534/4885 |
| US-20110028447-A1 | INDAZOLE DERIVATIVES | CNR1, CNR2, GPR119 | CTSS 2697/4885CTSL 4060/4885CTSB 2325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.